Pathogenesis, Diagnosis, and Therapy

Nephrogenic systemic fibrosis (NSF) is a newly recognized disorder occurring exclusively in patients with renal failure. Exposure to gadolinium-based magnetic resonance (MR) contrast media has been associated with subsequent development of NSF. Nephrogenic systemic fibrosis is characterized by skin induration preferentially affecting the extremities. In addition, involvement of internal organs occurs, which leads ultimately to death. Skin biopsy is important for confirmation of the diagnosis. The main therapeutic goal is restoration of renal function. To reduce the risk of NSF, renal function must be determined before exposure to gadolinium-containing MR contrast agents. Gadolinium-based MR contrast media should be avoided in the presence of advanced renal failure with estimated glomerular filtration rate below 30 ml/min/1.73 m 2 , unless the diagnostic information is essential and not available with noncontrast magnetic resonance imaging techniques. The recommended dose of contrast agent should not be exceeded. In addition, a sufficient period of time for elimination of the contrast agent from the body should be allowed before readministration of the contrast agent. (J Am Coll Cardiol 2009;53: 1621‐8) © 2009 by the American College of Cardiology Foundation

[1]  Harold I Feldman,et al.  Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Martin R Prince,et al.  Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.

[3]  Diego R Martin,et al.  Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.

[4]  M. Panesar,et al.  Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation , 2008, Clinical transplantation.

[5]  A. Molen.  NEPHROGENIC SYSTEMIC FIBROSIS AND THE ROLE OF GADOLINIUM CONTRAST MEDIA , 2008 .

[6]  J. Penfield.  Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents , 2008, Pediatric Nephrology.

[7]  J. Ranville,et al.  Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. , 2008, Kidney international.

[8]  R. Reilly.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[9]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[10]  P. Marckmann,et al.  Nephrogenic systemic fibrosis: epidemiology update , 2008, Current opinion in nephrology and hypertension.

[11]  A. Kribben,et al.  Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention. , 2008, Minerva Medica.

[12]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[13]  Jane O. Schell,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future , 2008, Seminars in dialysis.

[14]  S. Cowper,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment , 2008, Seminars in dialysis.

[15]  R. Rodby.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Dialytic Therapies to Prevent NSF Following Gadolinium Exposure in High‐Risk Patients , 2008, Seminars in dialysis.

[16]  R. Reilly,et al.  What nephrologists need to know about gadolinium , 2007, Nature Clinical Practice Nephrology.

[17]  R. Woolson,et al.  Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  W. Eubank,et al.  Steady‐state free precession MRA of the renal arteries: Breath‐hold and navigator‐gated techniques vs. CE‐MRA , 2007, Journal of magnetic resonance imaging : JMRI.

[20]  Sudhir V. Shah,et al.  New insights into nephrogenic systemic fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.

[21]  L. Chibnik,et al.  Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. , 2007, Arthritis and rheumatism.

[22]  M. Reiser,et al.  Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie , 2007, Der Radiologe.

[23]  Z. Endre.  Nephrogenic systemic fibrosis: is any contrast safe in renal failure? , 2007, Internal medicine journal.

[24]  H. Thomsen,et al.  Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? , 2007, Acta radiologica.

[25]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[26]  M. Goyen,et al.  Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide , 2007, European Radiology.

[27]  K. Ballen.  Targeting the stem cell niche: squeezing blood from bones , 2007, Bone Marrow Transplantation.

[28]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[29]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[30]  E. Fleck,et al.  Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession , 2007, The International Journal of Cardiovascular Imaging.

[31]  M. Lucia,et al.  A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis , 2007, Nature Clinical Practice Nephrology.

[32]  S. Morcos.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[33]  V. Runge,et al.  Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.

[34]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[35]  S. Textor,et al.  Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. , 2007, Nephrology, Dialysis and Transplantation.

[36]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[37]  H. Thomsen.  Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide , 2006, European Radiology.

[38]  M. Pittelkow,et al.  Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. , 2006, Annals of internal medicine.

[39]  Yoshiaki Tanaka,et al.  Dialyzability of gadodiamide in hemodialysis patients , 2006, Radiation Medicine.

[40]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  S. Cowper,et al.  Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.

[42]  S. Cowper.  Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  R. Elenitsas,et al.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.

[44]  S. Jimenez,et al.  Involvement of skeletal muscle in dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy) , 2004, Muscle & nerve.

[45]  T. Gambichler,et al.  Nephrogenic fibrosing dermopathy , 2004, Clinical and experimental dermatology.

[46]  P. Leboit,et al.  Nephrogenic fibrosing dermopathy: two pediatric cases. , 2003, The Journal of pediatrics.

[47]  C. Heeschen,et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.

[48]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. , 2003, The American Journal of dermatopathology.

[49]  M. Miyazaki,et al.  Peripheral MR angiography: separation of arteries from veins with flow-spoiled gradient pulses in electrocardiography-triggered three-dimensional half-Fourier fast spin-echo imaging. , 2003, Radiology.

[50]  R. Swartz,et al.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.

[51]  F. Maes,et al.  Improved visualization of coronary arteries using a new three-dimensional submillimeter MR coronary angiography sequence with balanced gradients. , 2002, AJR. American journal of roentgenology.

[52]  F. S. Pereles,et al.  Thoracic aortic dissection and aneurysm: evaluation with nonenhanced true FISP MR angiography in less than 4 minutes. , 2002, Radiology.

[53]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[54]  S. Swan,et al.  Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.

[55]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[56]  S. Cowper,et al.  Nephrogenic systemic fibrosis: an overview. , 2008, Journal of the American College of Radiology : JACR.

[57]  F. Artunc,et al.  Nephrogene systemische Fibrose , 2008, Deutsche medizinische Wochenschrift.

[58]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[59]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[60]  A. Rosenkranz,et al.  Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? , 2007, Wiener klinische Wochenschrift.

[61]  N. Liégeois,et al.  Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. , 2003, Journal of the American Academy of Dermatology.

[62]  D. Cohen,et al.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.